Halozyme Therapeutics, Inc. (HALO) AI Stock Analysis

Halozyme Therapeutics, Inc. operates as a biopharmaceutical technology platform company with operations in the United States, Switzerland, Ireland, Belgium, Japan, and elsewhere. Its primary platform is the ENHANZE drug delivery technology, which uses a patented recombinant human hyaluronidase enzyme (rHuPH20) to enable subcutaneous delivery of injectable biologics, monoclonal antibodies, and small molecules. Its commercial product is Hylenex recombinant. Halozyme partners with pharmaceutical companies including F. Hoffmann-La Roche and Pfizer to develop treatments such as Perjeta, RITUXAN HYCELA, MabThera SC, HYQVIA, Tecentriq, OCREVUS, and DARZALEX across oncology, immunodeficiency, and autoimmune indications.

Revenue increased from $443.3M in FY2021 to $1.40B in FY2025, reflecting a 37.6% increase in FY2025. Gross margin was 83.6% in FY2025, compared to 81.6% in FY2021 and 84.3% in FY2024. Operating margin reached 57.5% in FY2025, while net income was $316.9M, yielding a net margin of 22.7% and EPS of $4.13. For the trailing twelve months, revenue reached $1.66B with a profit margin of 24.9% and an operating margin of 59.8%. For the latest quarter ended June 30, 2026, quarterly revenue grew 47.7% year-over-year, and quarterly earnings grew 42.9%.

As of June 30, 2026, Halozyme held $231.0M in cash and short-term investments against total debt of $2.15B, resulting in net debt of $1.92B. Shareholders' equity was $143.5M, total assets were $2.58B, the current ratio stood at 2.71, and the debt-to-equity ratio was 14.95. In FY2025, the company generated operating cash flow of $651.6M and free cash flow of $644.6M while spending $7.0M on capital expenditures. Halozyme deployed $342.4M toward share buybacks in FY2025, contributing to a 16.0% reduction in share count over 5 years.

Halozyme trades at a trailing P/E of 35.6x, compared to 24.6x for the median of its US-listed Healthcare peers. Its forward P/E of 11.5x sits below the peer median of 17.3x. Enterprise value stands at $14.68B, with an EV-to-revenue multiple of 8.8x and an EV-to-EBITDA multiple of 15.9x, compared to the peer median EV-to-EBITDA of 12.0x. Price-to-sales is 8.3x versus the peer median of 4.1x. Halozyme's stock gained 82.2% over the trailing 1-year period, outperforming the S&P 500 return of 16.8%, and gained 222.7% over 5 years compared to 83.0% for the index.

Wall Street coverage includes 5 Strong Buy, 2 Buy, and 2 Hold ratings, with zero Sell or Strong Sell recommendations. The mean price target is $108.78, which is 10.7% below the October 16, 2026 closing price of $121.84. For the fiscal year ending December 31, 2026, analysts estimate EPS of $8.84, representing 112.9% growth, on revenue of $1.88B. Halozyme beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 2, 2026.

This page is an AI-written research summary of Halozyme Therapeutics, Inc. (HALO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: HALO income statement, HALO balance sheet, HALO key metrics, HALO analyst forecast, HALO chart. See the HALO stock overview for the latest quote and news.